You are here: Industry Insights > Piramal Pharma

News List

Piramal Pharma Solutions invests ~$32 mn in its Riverview Michigan facility expresspharma
December 10, 2020
Piramal Pharma’s Pharma Solutions business announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of active pharma ingredients (APIs).
Piramal Pharma to acquire Navin Fluorine’s stake in Convergence Chemicals at Rs 65.10 cr expresspharma
October 30, 2020
This deal will increase Piramal Pharma’s stake to 100 per cent in Convergence Chemicals.
Piramal Pharma’s consumer division launches Tri-Activ disinfectant spray for COVID-19 expresspharma
October 29, 2020
The company claims that for multi-surfaces it is “99.9 per cent effective against the COVID-19 virus in one minute.
Piramal Pharma announces completion of 20 per cent strategic growth investment by Carlyle expresspharma
October 12, 2020
Carlyle completes investment in Piramal Pharma; capital infusion to accelerate Piramal Pharma’s organic and inorganic growth plans.
Piramal Pharma completes stake sale to Carlyle pharmaceutical-technology
October 10, 2020
Piramal Enterprises subsidiary Piramal Pharma has concluded the previously announced sale of its 20% stake to US-based global investment firm Carlyle Group in a deal valued approximately Rs35.234bn ($480m).
CII approves Carlyle’s acquisition of stake in Piramal Pharma for $490m pharmaceutical-technology
September 15, 2020
The Competition Commission of India (CCI) has approved the sale of 20% of the issued and paid-up equity share capital in Piramal Pharma, a subsidiary of Piramal Enterprises, to Carlyle Group for approximately $490m.
Carlyle Pays $490M for 20% of Piramal Pharma contractpharma
July 06, 2020
Will integrate Piramal Enterprises’ pharma businesses into its subsidiary Piramal Pharma Limited.
Carlyle Group to acquire 20 per cent stake in Piramal Pharma expresspharma
June 28, 2020
The transaction worth $490 million is expected to close in 2020, subject to customary closing conditions and regulatory approvals.
Piramal Pharma invests $10 million to expand its high potency API capability in US expresspharma
June 21, 2019
Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), announced the opening of a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low